

JUN 21 2005

K 050583

510(k) Summary of Safety and Effectiveness

Date: March 4, 2005

Submitter: GE Medical Systems *Information Technologies*
4502 Woodland Corporate Boulevard
Tampa, FL 33614 USA

Contact Person: Tyler Sedone
Senior Regulatory Affairs Specialist
Phone: 813-887-2133
Fax: 813-887-2545

Device: Trade Name: Corometrics Model 250 Series Maternal/Fetal Monitor

Common/Usual Name: Maternal/Fetal Monitor

Classification Names: 21 CFR 884.2740 System, Monitoring, Perinatal

Predicate Devices: K032252 Corometrics Model 120is Maternal/Fetal Monitor
K022834 DINAMAP PRO 1000 with SuperSTAT
K040831 Datex Ohmeda SpO2
K012891/K021089/K030930 Nellcor SpO2
K033296 Masimo SpO2

Device Description: The Corometrics 250 Series Maternal/Fetal Monitoring System consists of the following features/options that can be available in multiple configurations:

- fetal heart rate (via Doppler Ultrasound or FECG)
- maternal uterine activity (via intrauterine pressure catheter or tocotransducer)
- fetal movement detection
- maternal non-invasive blood pressure (clinician prompted or automatic)
- maternal pulse oximetry
- maternal heart/pulse rate (MECG) and ECG waveform "snapshot"

Intended Use: The Corometrics 250 Series Maternal/Fetal Monitoring System is intended for monitoring fetal and maternal vital signs: fetal heart rate; optional fetal movement detection, FHR and UA alarms; maternal uterine activity; heart/pulse rate, blood pressure and %SpO₂.

Technology: The Corometrics 250 Series Maternal/Fetal Monitor employs the same fundamental scientific technology as the predicate devices.

Test Summary: The Corometrics 250 Series Maternal/Fetal Monitor complies with the voluntary standards as detailed in Section 9 of this submission. The following quality assurance measures were applied to the development:

- Requirements specification review
- Code inspections
- Software and hardware testing
- Safety testing
- Environmental testing
- Final validation

Conclusion: The results of these measurements demonstrated that the Corometrics 250 Series Maternal/Fetal Monitor is as safe and effective, and as the predicate device.



JUN 21 2005

Food and Drug Administration
9200 Corporate Boulevard
Rockville, MD 20850

Mr. Tyler Sedone
Senior Regulatory Affairs Specialist
GE Medical Systems Information Technologies
4502 Woodland Corporate Boulevard
TAMPA FL 33614

Re: K050583
Trade/Device Name: Corometrics 250 Series Maternal/Fetal Monitoring System
Regulation Number: 21 CFR §884.2740
Regulation Name: Perinatal monitoring system and accessories
Regulatory Class: II
Product Code: HGM
Dated: June 2, 2005
Received: June 13, 2005

Dear Mr. Sedone:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other	-	240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known): **K 0505 83**

Device Name: Corometrics Model 250 Series Maternal/Fetal Monitoring System

Indications For Use:

I. Fetal Surveillance

A Corometrics 250 Series Maternal/Fetal Monitoring System is used for non-invasive and invasive monitoring of the fetus during the antepartum period as well as throughout labor and delivery (i.e. fetal heart rate and uterine activity monitoring). Fetal movement detection and fetal heart rate alarm options (user selectable high/low and poor signal quality alarms) are available.

II Maternal Monitoring

A Corometrics 250 Series Maternal/Fetal Monitoring System is intended for monitoring maternal vital signs to help assess maternal well-being. The vital signs which can be measured with these monitor configurations are summarized as follows:

NOTE: Maternal vital signs provided by the monitor should only be used as an adjunct in patient assessment in conjunction with clinical signs and symptoms.

Blood Pressure: The monitor is intended for use in the non-invasive monitoring of maternal blood pressure (NBP). This monitor is not intended for use in the neonatal or pediatric blood pressure monitoring.

Pulse Oximetry. The monitor is intended for use in the non-invasive monitoring of maternal functional oxygen saturation of arterial hemoglobin (M_{SpO2}).

Heart/Pulse Rate. The monitor is intended for use in the non-invasive monitoring of the maternal heart/pulse rate. Additionally, an M_{ECG} waveform "snapshot" may be displayed and printed.

NOTE: Only the maximum configuration provides both maternal heart rate and pulse rate data.

Prescription Use (Per 21 CFR 801.109)

OR

Over-The-Counter Use

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Nancy Brogdon

(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices

510(k) Number **K050583**